Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis (original) (raw)

• Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584–593
  Article CAS Google Scholar
• Roudier MP et al. (2004) Histological, immunophenotypic and histomorphometric characterisation of prostate cancer bone metastasis. In The Biology of Skeletal Metastases, 311–339 (Eds Keller ET and Chung LWK) Boston: Kluwer Academic Publishers
  Chapter Google Scholar
• Seibel MJ (2005) Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2: 504–517
  Article CAS Google Scholar
• Nielsen OS et al. (1991) Bone metastases: pathophysiology and management policy. J Clin Oncol 9: 509–524
  Article CAS Google Scholar
• Roodman GD (1996) Advances in bone biology: the osteoclast. Endocr Rev 17: 308–332
  CAS PubMed Google Scholar
• Simonet WS et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309–319
  Article CAS Google Scholar
• Tsuda E et al. (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234: 137–142
  Article CAS Google Scholar
• Bucay N et al. (1998) Osteoprotegerin deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260–1268
  Article CAS Google Scholar
• Yasuda H (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OCIF/OPG inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329–1337
  Article Google Scholar
• Yasuda H et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sci USA 95: 3597–3602
  Article CAS Google Scholar
• Lacey DL et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165–176
  Article CAS Google Scholar
• Anderson DM et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175–179
  Article CAS Google Scholar
• Wong BR et al. (1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186: 2075–2080
  Article CAS Google Scholar
• Matsuzaki K et al. (1998) Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 246: 199–204
  Article CAS Google Scholar
• Burgess TL et al. (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145: 527–538
  Article CAS Google Scholar
• O'Brien EA et al. (2000) Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 274: 281–290
  Article CAS Google Scholar
• Lacey DL et al. (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157: 435–448
  Article CAS Google Scholar
• Hsu H et al. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96: 3540–3545
  Article CAS Google Scholar
• Body J-J et al. (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (Suppl): S887–S892
  Article Google Scholar
• Whyte MP et al. (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347: 175–184
  Article CAS Google Scholar
• Hughes AE et al. (2000) Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24: 45–48
  Article CAS Google Scholar
• Theoleyre T et al. (2004) The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15: 457–475
  Article CAS Google Scholar
• Standal T et al. (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100: 3002–3007
  Article CAS Google Scholar
• Mosheimer BA et al. (2005) Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 90: 2964–2971
  Article CAS Google Scholar
• Keller ET and Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91: 718–729
  Article CAS Google Scholar
• Brown JM et al. (2004) OPG, RANKL, and RANK in cancer metastasis: expression and regulation. In The Biology of Skeletal Metastases, 149–172 (Eds Keller ET and Chung LWK) Boston: Kluwer Academic Publishers
  Chapter Google Scholar
• Mundy GR (1997) Mechanisms of bone metastasis. Cancer 80 (Suppl): S1546–S1556
  Article Google Scholar
• Keller ET and Brown JM (2003) Osteoprotegerin, receptor activator of NFκB (RANK) and RANK ligand in cancer. In Research Advances in Cancer 3, 81–93 (Ed Mohan RM) Kerala: Global Research Network
  Google Scholar
• Dunstan CR (2005) The role of RANK, RANK ligand and osteoprotegerin in the lytic effects and growth of bone metastases. In Textbook of Bone Metastases, 51–62 (Eds Jasmin C et al.) Chichester: John Wiley and Sons, Ltd
  Google Scholar
• Bhatia P et al. (2005) Expression of receptor activator of NF-kappa B is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11: 162–165
  CAS PubMed Google Scholar
• Reinholz MM et al. (2002) Differential gene expression of TGF-beta family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res Treat 74: 255–269
  Article CAS Google Scholar
• Brown JM et al. (2001) Osteoprotegerin and RANK ligand expression in prostate cancer. Urology 57: 611–616
  Article CAS Google Scholar
• Heider U et al. (2003) Expression of receptor activator of nuclear factor κB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9: 1436–1440
  CAS PubMed Google Scholar
• Farrugia AN et al. (2003) Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438–5445
  CAS PubMed Google Scholar
• Ito R et al. (2003) Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch 443: 146–151
  Article CAS Google Scholar
• Pearse RN et al. (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98: 11581–11586
  Article CAS Google Scholar
• Lipton A et al. (2002) Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8: 2306–2310
  CAS PubMed Google Scholar
• Seidel C et al. on behalf of The Nordic Myeloma Study Group (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98: 2269–2271
• Kyrtsonis MC et al. (2004) Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol 72: 252–258
  Article CAS Google Scholar
• Martinetti A et al. (2004) Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. Endocr Relat Cancer 11: 771–779
  Article CAS Google Scholar
• Mizutani Y et al. (2004) Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma. Cancer 101: 1794–1802
  Article CAS Google Scholar
• Brown JM et al. (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7: 2977–2983
  CAS PubMed Google Scholar
• Eaton CL et al. (2004) Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59: 304–310
  Article CAS Google Scholar
• Jung K et al. (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111: 783–791
  Article CAS Google Scholar
• Jung K et al. (2003) Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 170: 2302–2305
  Article Google Scholar
• Terpos E et al. (2003) Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102: 1064–1069
  Article CAS Google Scholar
• Grimaud E et al. (2003) Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163: 2021–2031
  Article CAS Google Scholar
• Sezer O et al. (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101: 2094–2098
  Article CAS Google Scholar
• Vanderkerken K et al. (2003) Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 194: 196–206
  Article CAS Google Scholar
• Sordillo EM and Pearse RN (2003) RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 97 (Suppl): S802–S812
  Article Google Scholar
• Doran PM et al. (2004) Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. Exp Hematol 32: 351–359
  Article CAS Google Scholar
• Capparelli C et al. (2000) Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60: 783–787
  CAS PubMed Google Scholar
• Morony S et al. (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61: 4432–4436
  CAS PubMed Google Scholar
• Zhang J et al. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235–1244
  Article CAS Google Scholar
• Bekker PJ et al. (2004) A single dose controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in post-menopausal women. J Bone Miner Res 19: 1059–1066
  Article CAS Google Scholar
• Onyia JE et al. (2004) Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. J Pharmacol Exp Ther 309: 369–379
  Article CAS Google Scholar
• Viereck V et al. (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291: 680–686
  Article CAS Google Scholar
• Mackie PS et al. (2001) Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84: 951–958
  Article CAS Google Scholar
• Pan B et al. (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-α converting enzyme (TACE). J Bone Miner Res 19: 147–154
  Article CAS Google Scholar
• Corey E et al. (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9: 295–306; Erratum in: Clin Cancer Res 9: 1574–1575
  CAS PubMed Google Scholar
• Honore P et al. (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6: 521–528
  Article CAS Google Scholar
• Luger NM et al. (2001) Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61: 4038–4047
  CAS PubMed Google Scholar
• Morony S et al. (2005) The RANKL inhibitor osteoprotegerin (OPG) causes greater suppression of bone resorption and hypercalcemia compared to bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 146: 3235–3243
  Article CAS Google Scholar
• Akatsu T et al. (1998) Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 23: 495–498
  Article CAS Google Scholar
• Zhang J et al. (2003) Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res 63: 7883–7890
  CAS PubMed Google Scholar
• Holen I et al. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62: 1619–1623
  CAS PubMed Google Scholar
• Shipman CM and Croucher PI (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63: 912–916
  CAS PubMed Google Scholar
• Hausler KD et al. (2004) Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res 19: 1873–1881
  Article CAS Google Scholar
• Zhou H et al. (2001) A novel osteoblast-derived C-type lectin that inhibits osteoclast formation. J Biol Chem 276: 14916–14923
  Article CAS Google Scholar
• Hu YS et al. (2004) Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts. J Bone Miner Res 19: 89–99
  Article CAS Google Scholar
• Zhou H et al. (2002) Osteoclast inhibitory lectin, a family of new osteoclast inhibitors. J Biol Chem 277: 48808–48815
  Article CAS Google Scholar
• Bendre MS et al. (2003) Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33: 28–37
  Article CAS Google Scholar
• Huang L et al. (2003) Receptor activator of NF-κB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol Pathol 56: 116–120
  Article CAS Google Scholar
• Kumamoto H and Ooya K (2004) Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-κB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. J Oral Pathol Med 33: 46–52
  Article CAS Google Scholar
• Atkins GJ et al. (2000) Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 15: 640–649
  Article CAS Google Scholar
• Good CR et al. (2002) Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors. J Surg Oncol 79: 174–179
  Article Google Scholar
• Sezer O et al. (2002) Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 99: 4646–4647
  Article CAS Google Scholar
• Giuliani N et al. (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 3527–3533
  Article CAS Google Scholar
• Huang L et al. (2002) Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases. J Clin Pathol 55: 877–878
  Article CAS Google Scholar